A Phase I/II Study of Abatacept in the Treatment of Patients With Steroid Refractory Chronic Graft Versus Host Disease (cGVHD)
Latest Information Update: 09 Jun 2026
At a glance
- Drugs Abatacept (Primary)
- Indications Graft-versus-host disease
- Focus Adverse reactions
Most Recent Events
- 29 May 2026 Phase changed to phase 1/2, hence protocol was amended.
- 16 Jan 2024 Status changed from active, no longer recruiting to completed.
- 09 Jan 2023 Planned primary completion date changed from 1 Dec 2022 to 1 Jun 2023.